⏳ Fetching live dividend data...
Home › Calculator › ONCS Dividend Calculator 2026
OncoSec Medical Incorporated · NASDAQ
Price: $0.28 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ONCS → $13998435.22M in 10 years · $1,024,535,630,311.50/month
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ONCS position with:
Real after-tax yield depends on where you live and how you hold ONCS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 721.50% | 718.70% | $72,150 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 613.27% | 610.48% | $61,328 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 577.20% | 574.40% | $57,720 / yr |
| 🇬🇧 UK ISA | 0% | 721.50% | 718.70% | $72,150 / yr |
| 🇬🇧 UK Taxable | 8.75% | 658.37% | 655.57% | $65,837 / yr |
| 🇨🇦 TFSA | 0% | 721.50% | 718.70% | $72,150 / yr |
| 🇨🇦 CA Taxable | 25% | 541.13% | 538.33% | $54,113 / yr |
| 🇦🇺 Super (pension) | 15% | 613.27% | 610.48% | $61,328 / yr |
| 🇦🇺 AU Taxable | 30% | 505.05% | 502.25% | $50,505 / yr |
| 🇩🇪 DE Taxable | 26.375% | 531.20% | 528.40% | $53,120 / yr |
| 🇫🇷 FR Taxable | 30% | 505.05% | 502.25% | $50,505 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ONCS pays quarterly — 4 times per year. Next ex-div: TBD.
How ONCS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ONCS sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2023-02-09 | 40 | $1.37 | $55.00 | ||
| Sale | 2022-11-04 | 283 | $0.37 | $105.00 | ||
| A-Award | 2022-10-07 | 50,000 | — | — | ||
| Sale | 2022-08-05 | 284 | $0.71 | $202.00 | ||
| Sale | 2022-05-06 | 274 | $0.83 | $227.00 | ||
| A-Award | 2022-05-02 | 700,000 | — | — | ||
| Sale | 2022-02-09 | 409 | $0.88 | $360.00 | ||
| Sale | 2021-11-01 | 343 | $1.75 | $600.00 | ||
| Buy | 2021-08-23 | 20,000 | $1.89 | $37.8K | ||
| Buy | 2021-08-23 | 4,000 | $1.88 | $7.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ONCS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →